TBPH Theravance Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TBPH

Price (delayed)

$9.515

Market cap

$458.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1

Enterprise value

$467.07M

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives ...

Highlights
TBPH's revenue is up by 12% year-on-year and by 5% since the previous quarter
The gross profit has grown by 12% YoY and by 5% from the previous quarter
The net income has plunged by 106% YoY but it has grown by 3.2% from the previous quarter
Theravance Biopharma's EPS has shrunk by 108% YoY and by 64% QoQ
The company's quick ratio has shrunk by 59% YoY and by 19% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.theravance.com
Peers: MDWD MEIP CTLT CPRX

Key stats

What are the main financial stats of TBPH
Market
Shares outstanding
48.16M
Market cap
$458.29M
Enterprise value
$467.07M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
9.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.13
Earnings
Revenue
$57.42M
EBIT
-$46.92M
EBITDA
-$40.77M
Free cash flow
-$27.97M
Per share
EPS
-$1
Free cash flow per share
-$0.51
Book value per share
$4.28
Revenue per share
$1.04
TBVPS
$6.91
Balance sheet
Total assets
$382M
Total liabilities
$169M
Debt
$49.16M
Equity
$213M
Working capital
$108.77M
Liquidity
Debt to equity
0.23
Current ratio
5.39
Quick ratio
4.87
Net debt/EBITDA
-0.22
Margins
EBITDA margin
-71%
Gross margin
100%
Net margin
-96.1%
Operating margin
-97.6%
Efficiency
Return on assets
-12.4%
Return on equity
-19.9%
Return on invested capital
-12.7%
Return on capital employed
-13.1%
Return on sales
-81.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
1.55%
1 week
4.33%
1 month
2.42%
1 year
-15.35%
YTD
-15.35%
QTD
6.08%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$57.42M
Gross profit
$57.42M
Operating income
-$56.04M
Net income
-$55.19M
Gross margin
100%
Net margin
-96.1%
Theravance Biopharma's net margin has shrunk by 106% YoY but it has increased by 8% QoQ
The net income has plunged by 106% YoY but it has grown by 3.2% from the previous quarter
Theravance Biopharma's operating margin has increased by 46% YoY and by 21% QoQ
The operating income is up by 39% YoY and by 17% QoQ

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
2.22
P/S
9.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.13
Theravance Biopharma's EPS has shrunk by 108% YoY and by 64% QoQ
TBPH's equity has dropped by 52% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 4.3% higher than the last 4 quarters average of 2.1
The P/S is 37% lower than the 5-year quarterly average of 14.3 and 19% lower than the last 4 quarters average of 11.2
TBPH's revenue is up by 12% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is Theravance Biopharma business performance
The company's return on assets has shrunk by 107% YoY and by 9% QoQ
The ROIC has plunged by 107% YoY but it has grown by 19% from the previous quarter
Theravance Biopharma's return on sales has shrunk by 104% YoY but it has increased by 21% QoQ
The ROE has plunged by 101% YoY and by 17% from the previous quarter

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 126% more than its total liabilities
The company's quick ratio has shrunk by 59% YoY and by 19% QoQ
TBPH's current ratio has dropped by 56% year-on-year and by 15% since the previous quarter
Theravance Biopharma's debt is 77% lower than its equity
The debt to equity has soared by 92% YoY and by 10% QoQ
TBPH's equity has dropped by 52% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.